PF-Atlas › Clinical Trials › NCT03224351
A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis
VX-659 · Phase 2
Registry ID
NCT03224351
Phase
Phase 2
Status
Completed
Drug / intervention
VX-659
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2017-08-08
Enrollment
124
Locations
47
About this trial
This is a Phase 2, randomized, double-blind, placebo- and tezacaftor/ivacaftor (TEZ/IVA)-controlled, parallel-group, 3-part, multicenter study designed to evaluate the safety and efficacy of VX-659 in triple combination (TC) with TEZ and IVA in subjects with cystic fibrosis (CF) who are homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene (F/F genotype), or who are heterozygous for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ, IVA, or TEZ/IVA (F/MF genotypes).
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT03224351 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.